ResTORbio stops testing lead drug for respiratory illness; shares crash

Shares of drug developer ResTORbio Inc plunged more than 80% to a record low on Friday after a late-stage trial failure prompted the company to abandon testing its lead drug as a treatment for respiratory illness.

The company, however, said it continues to test the drug, RTB101, in other conditions, including Parkinson’s disease.